TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
Phase 2
Completed
NCT00694629
| Condition | Pulmonary Tuberculosis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Centers for Disease Control and Prevention |
|---|
| Status | Completed |
|---|
| Enrollment | 334 participants |
|---|
| Interventions | rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg |
|---|
| Start date | Dec, 2008 |
|---|
| Completion date | Jun, 2013 |
|---|
| Results posted | Jul 23, 2026 |
|---|
Summary
This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment. Participants were randomized to receive either a standard rifampin-based regimen (RHZE) or a rifapentine-substituted regimen (PHZE). An extension study evaluated higher daily doses of rifapentine (10, 15, and 20 mg/kg). The primary endpoint was sputum culture conversion at 8 weeks. Secondary outcomes included time to culture conversion, safety, and treatment discontinuation.
Participants With Negative Sputum Culture at 8 Weeks
8 weeks. · participants
| Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol | 52 participants |
|---|
| lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 62 participants |
|---|
| Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 59 participants |
|---|
| Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 54 participants |
|---|
Participants Who Discontinued Treatment During Intensive Phase
8 weeks · participants
| Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol | 11 participants |
|---|
| lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 5 participants |
|---|
| Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 5 participants |
|---|
| Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 9 participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.